#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma
Click here to read this study in Lancet Oncology.
©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
RelatedReports
